Sermorelin is a synthetic peptide that functions as an analog of growth hormone-releasing hormone (GHRH), a naturally occurring hormone produced by the hypothalamus. GHRH stimulates the pituitary gland to produce and release growth hormone (GH). Sermorelin was initially developed and approved for the treatment of growth hormone deficiency in children, as described by the FDA. Its mechanism involves binding to GHRH receptors on pituitary cells, thereby promoting the pulsatile secretion of growth hormone. Unlike directly administering growth hormone, Sermorelin aims to restore a more physiological pattern of GH release using the body's own regulatory mechanisms. This method minimizes some of the negative feedback loops that can occur with exogenous GH administration. Sermorelin is administered via subcutaneous injection and requires a prescription. Its use is primarily directed by licensed medical professionals.
Deep dive
Tap a section to expand.
Known interactions
Compound-pair rule
Caution
Same GH/IGF-1 axis as above; a GHRH analog plus exogenous IGF-1 is redundant.
Same-axis caution; provider oversight.
Compound-pair rule
Caution
Two GHRH-type analogs push the same node of the axis; redundant.
Same-axis redundancy; usually pick one.
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
- FDA (U.S. Food and Drug Administration)
- PubChem (National Library of Medicine)
- DrugBank (University of Alberta)
- NIH ODS (National Institutes of Health Office of Dietary Supplements)
- Examine.com
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the peptide category or studied for the same goals.
